Newsroom - BioNTech
WEBWelcome to the BioNTech Newsroom. In this section you can find a variety of media materials and useful information to download. Media Downloads. Conference "Working Together to Promote Vaccine Equity for Africa", December 18, 2023. Africa Vaccine Equity Conference 1. Africa Vaccine Equity Conference 2. Africa Vaccine Equity Conference 3.
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety ...
WEBApr 1, 2021 · Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and ...
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBDec 11, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
Pfizer and BioNTech Announce Positive Topline Data for mRNA …
WEBOct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAug 22, 2024 · The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech...
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
WEBDec 10, 2020 · Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid-19 ...
FDA Approves First COVID-19 Vaccine
WEBFDA approved the first COVID-19 vaccine, which has been known as the Pfizer-BioNTech COVID-19 Vaccine, and is now marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease...
BioNTech Announces Positive Topline Phase 2 Results for mRNA ...
WEBJul 30, 2024 · BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma. 30 July 2024. PDF Version. Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab.
FDA Approves Pfizer Vaccine: Live Updates - The New York Times
WEBAug 23, 2021 · Full federal approval for the Pfizer-BioNTech coronavirus vaccine for those 16 and older is opening the way for institutions like the military, corporate employers, hospitals and school...
FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better …
WEBSep 11, 2023 · As part of today’s actions, the bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. Data Supporting the Updated mRNA COVID-19 Vaccines...